Latest News from BioProcess Insider
Keeping supply chains resilient in times of crisis
Robust risk management can offset supply chain problems that have been further aggravated by COVID-19, says Samsung Bioepis’ Thomas Newcomer.
Hanmi makes move into the mRNA CDMO space
Hanmi Fine Chemical says the COVID-19 pandemic has increased the demand for RNA raw materials, causing it to launch CDMO services in relevant fields.
Podcast: Opening the gates for women in biotech
There is no lack of talented women in the biotech space but the gates blocking their progression must be open for them to fully realize their potential, says consultant Nadine Ritter.
High cost of complex biomanufacturing ‘a problem worth solving,’ says Waters
With the cost of manufacturing accounting for as much as 70% for cell and gene therapies, industry must look to bioprocessing efficiencies and collaboration, says Waters Corporation.
Moderna: ‘Speed to market approach’ for mRNA flu vaccine success
Inherent challenges to traditional flu vaccine manufacturing can easily be overcome with messenger RNA (mRNA) says Moderna, which is moving a candidate into Phase III trials.
CAR-T approvals marred by autologous manufacturing limitations, says Allogene
Autologous therapies have not kept up with demand says Allogene Therapeutics, which claims only off-the-shelf cell therapies can serve larger patient populations.
Standardized handling practices would help cell therapy sector, study
Cell therapy developers need uniform handling, storage, and usage methods say the authors of a new report examining how the market for centrally manufactured products is evolving.
Lithuanian CDMO Northway invests $40m in MA plant
Northway will open a facility in Waltham offering microbial and mammalian cell line development and upstream and downstream process advancement.
Korean CDMO enters US with BMS plant buy
Lotte is set to buy Bristol-Myers Squibb’s (BMS) facility in East Syracuse, which it says will serve its CDMO business in the US.
PCI forks out $100m to expand New England plant
The Philadelphia-based CDMO will expand its capacity in sterile lyophilization technology and aseptic liquid fill/finish to stay ahead of demand.
Bayer elusive on $2.2bn manufacturing revamp plan
Bayer says a three-year production reorganization will modernize its manufacturing network and streamline its supply chain, but specific details remain scarce.
Merck completes $1bn HPV vaccine expansion in Virginia
Merck & Co. has added 120,000 square feet of manufacturing capacity at its Rockingham County site to support continued scale-up of its Gardasil HPV vaccines.
Abzena bags $65m to expand manufacturing capacity
Abzena has secured $65 million in additional funding to expand its production facilities to meet the increased demand in the industry.
ThermoGenesis entering the CDMO space
ThermoGenesis has leased a facility in Sacramento, California to house its newly launched CDMO cell therapy business TG Biosynthesis.
UK reports 9% yearly growth in CGT clinical trials
CGT Catapult says the UK is a “world leader” in developing advanced therapies after publishing a 2021 clinical trials database and report.